Pharma BD Deal Intelligence

Ona Therapeutics S.L. / WuXi XDC Cayman Inc.

2026 · Licensing/Option · Complete

WuXi XDC out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics, granting Ona an exclusive global license to develop an antibody-drug conjugate candidate against a single undisclosed target. WuXi XDC receives an undisclosed upfront payment plus development, regulatory and sales milestone payments and tiered royalties on net sales upon commercialization. WuXiTecan-2 features a hydrophilic linker that delivers enhanced ADC stability. Ona Therapeutics is a Barcelona-based biotech developing first-in-class ADCs for treatment-resistant cancers; WuXi XDC is a global CRDMO specializing in ADCs and bioconjugates. DATA NOTE: no financial figures were disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals